Abstract:Cong-Li Jia, 1 Fu Yang, 2 Rui-Ning Li 3 1 Weifang Medical College, Weifang, Shandong, People's Republic of China; 2 Department of Hepatobiliary Surgery, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China; 3 Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China Correspondence: Fu Yang Department of Hepatobiliary Surgery, First Affiliated Hospital of Kunming Medical University, No. 295, Xi Chang Road, Kunming, Yunnan, 650032, People's Republic of China Tel +86 13888428338 Email Purpose: To identify the potential differential genes between primary and metastatic melanoma, screen out immune-related genes in core genes and analyze their immune correlation, thus searching for the early diagnostic biomarkers of cutaneous malignant melanoma (CMM) and the targets of curbing metastasis. Materials and Methods: We analyzed two microarray datasets (GSE8401 and GSE46517) derived from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) between primary and metastatic melanoma were screened out using the GEO2R tool. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed to identify the functions and pathways of DEGs. We analyzed protein–protein interaction of these DEGs based on the Search Tool for the Retrieval of Interacting Genes database and showed by Cytoscape software. In addition, the online Gene Expression Profiling Interactive Analysis tool (GEPIA) was used to analyze the prognostic value of hub genes expressed in metastatic melanoma patients. Immune-related genes in hub genes were screened and further analyzed. Results: A total of 178 upregulated DEGs and 4 downregulated DEGs were identified. 23 terms and 4 pathways were confirmed related to metastatic melanoma. Ten hub genes with a high degree of connectivity were found. Overexpression of three hub genes (DSG1, FLG, PKP1) (P< 0.01) was associated with metastasis and poor prognosis of CMM. Among them, the patients with overexpression of PKP1 suffered shorter survival. In addition, 2 immune-related genes (EGFR and CDH1) in hub genes were screened out and both of them were related to anti-tumor immunity, although their expression level did not affect the overall survival of CMM patients significantly. Conclusion: Our study suggests that DSG1, FLG and PKP1 were overexpressed in metastatic melanoma compared with primary melanoma, and overexpression of these three genes was an unfavorable prognostic factor ifor CMM patients, which may indicate that they are associated with promoting metastasis of malignant melanoma. EGFR and CDH1 play a crucial role in anti-tumor immunity for CMM. Further research is needed to explore the value of these genes in the inhibition of metastasis and treatment of CMM. Keywords: cutaneous malignant melanoma, metastasis, genes, PKP1, DSG1, FLG, CDH1, EGFR Cutaneous malignant melanoma is a highly malignant tumor originating from skin melanocytes, which is usually ignored as melanin nevus in the early stage. 1 Once metastasis occurs, the cure rate is low. The primary lesion is often seen in the lower extremities, and a few can occur in tissues and organs, such as digestive tract and eyes. CMM with insidious onset is prone to metastasis and diffusion. Currently, surgery combined with radiotherapy, chemotherapy and high-dose interferon are the main treatment methods for CMM, but the prognosis is unfavorable. Despite the rise of immunotherapy targeting certain mutated genes in recent years, the survival rate is still low. 2 Metastatic potential for CMM is very high, and the prognosis of patients with metastatic tumor is very poor. Molecular targeted therapy is the main strategy for the treatment of metastatic melanoma, however, lacking targets to inhibit tumor metastasis results that only a small number of patients can benefit. 3 Recent studies have focused on finding diagnostic biomarkers and therapeutic targets for malignant melanoma, but their focus is mostly on identifying gene expression differences between normal tissues and tumors, while few studies have explored genes differentially expressed between primary cancer and metastatic cancer. However, early melanoma treatment is often delayed due to misdiagnosis, and intervention before metastasis may be a promising strategy for improving survival. Due to this, it is urgent to find novel biomarkers in the genetic differences between primary and metastatic melanoma to guide early diagnosis and treatment. In this study, we sought to explore new indicators of metastasis in CMM and to provide new therapeutic targets for this disease. To d -Abstract Truncated-

Screening and identification of potential prognostic biomarkers in metastatic skin cutaneous melanoma by bioinformatics analysis

New Prognostic Biomarkers and Drug Targets for Skin Cutaneous Melanoma Via Comprehensive Bioinformatic Analysis and Validation

Identification of Potential Prognostic Biomarkers Associated With Cancerometastasis in Skin Cutaneous Melanoma

Identification and Validation of Three Risk Models in Skin Melanoma Based on Bioinformatics Analysis

Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis

Identification of significant genes with a poor prognosis in skin cutaneous malignant melanoma based on a bioinformatics analysis

Bioinformatical analysis identified significant genes in the PI3K-Akt signaling pathway relating with poor prognosis of skin cutaneous melanoma

Identification of Keratinocyte Differentiation-Involved Genes for Metastatic Melanoma by Gene Expression Profiles

Network-based Co-Expression Analysis for Exploring the Potential Diagnostic Biomarkers of Metastatic Melanoma

Identification of Key Candidate Genes Involved in Melanoma Metastasis

Comprehensive analysis and identification of key genes and signaling pathways in the occurrence and metastasis of cutaneous melanoma

Machine learning modeling and prognostic value analysis of invasion-related genes in cutaneous melanoma

Bioinformatics Analysis Identifies MicroRNAs and Target Genes Associated with Prognosis in Patients with Melanoma

Identification of Immune-Related Biomarkers Associated with Tumorigenesis and Prognosis in Skin Cutaneous Melanoma.

Identification of Prognostic Gene Biomarkers for Metastatic Skin Cancer Using Data Mining.

Identification of Potential Core Genes Between Primary and Metastatic Malignant Melanoma and Analysis of Their Immune Correlation

Potential Prognostic Predictors and Molecular Targets for Skin Melanoma Screened by Weighted Gene Co-expression Network Analysis

Analysis of differential gene immune infiltration and clinical characteristics of skin cutaneous melanoma based on systems biology and drug repositioning methods to identify drug candidates for skin cutaneous melanoma

Identification of a novel tumour microenvironment-based prognostic biomarker in skin cutaneous melanoma

Re-Exploring Biomarkers and Therapeutic Targets in Primary Melanoma Patients: Insights from Network-Based Analysis of Microarray Data

Screening Genes Associated with Melanoma Using a Combined Analysis of Mrna and Methylation Microarray